Antifungal agents: an overview. Part II.
The recent introduction of a new generation of antifungal drugs promises to alter significantly therapy for both systemic and superficial mycoses, in particular, onychomycosis. This article presents an in-depth review of the azoles (the triazoles itraconazole and fluconazole), the allylamines (naftifine and terbinafine), and the morpholine derivative amorolfine.
Gupta
A K
AK
Department of Medicine, Sunnybrook Health Science Centre, Toronto, Ontario, Canada.
Sauder
D N
DN
Shear
N H
NH
D000499:Allylamine / Q000031:analogs & derivatives / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use; D000935:Antifungal Agents / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001393:Azoles / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use; D003881:Dermatomycoses / Q000188:drug therapy; D006801:Humans; D009025:Morpholines / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use; D009281:Naphthalenes / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use; D014009:Onychomycosis / Q000188:drug therapy; D000077291:Terbinafine
D000935:Antifungal Agents; D001393:Azoles; D009025:Morpholines; D009281:Naphthalenes; D000499:Allylamine; C029178:naftifine; C038974:amorolfine; D000077291:Terbinafine